Cognition Therapeutics secures 20-year US patent for Alzheimer’s and dementia drug (opens in new tab)

Cognition Therapeutics announced on 16 June 2026 that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application 19/563,468 covering a polymorphic crystalline form of Zervimesine (CT1812), the company’s lead drug candidate. According to the company, the issued patent will provide protection for this formulation through 2045 and, if […] The post appeared first on <a href="